ESAT-6 and CFP-10 antigens as a biotechnology molecule substrate. Applications in medicine

Cover Page

Cite item

Full Text

Abstract

Recombinant technologies have been long widely used in medicine. This article presents a review on the application of medical technologies based on ESAT-6 and CFP-10 proteins in diagnostics and prevention of tuberculosis. ESAT-6 and CFP-10 are specific proteins whose genes are encoded in the RD-1 zone (region of difference) of M. tuberculosis. M. bovis BCG and in most nontuberculous mycobacteria lack the RD-1 genome fragment. The discovery of ESAT-6 and CFP-10 antigens allowed to make the first and so far, the only breakthrough in improving the diagnostics of latent tuberculosis infection after the first tuberculin skin test (TST) was implemented. The article describes the principle of action and the experience with diagnostic tools based on ESAT-6 and CFP-10 such as in vitro interferon-gamma release assays (IGRA) and in vivo recombinant tuberculosis allergen (RTA, Diaskintest). RTA is inoculated intradermally similar to TST followed by developing delayed-type immune reaction detected in the area closest to M. tuberculosis. Combined use of ESAT-6 and CFP-10 for early detection of tuberculosis infection allowed to ameliorate for many drawbacks related to TST. High sensitivity and specificity was confirmed for ESAT-6- and CFP-10-based tests, so that former BCG vaccination had no more effect on test results and lowered frequency of false positive results due to reaction to non-tuberculous mycobacteria. The results of a large-scale meta-analysis on studies with patients at high risk demonstrated that the risk of developing tuberculosis in subjects with positive vs. negative IGRA was increased by 9.35-fold (95% confidence interval (CI [6.48–13.49]), whereas for TST — by 4.24-fold (95% CI [3.3–5.46]). 95.1%, (95% CI [95.06–95.1]). Analyzing available publications demonstrated sufficient evidence base regarding efficacy of using ESAT-6–CFP-10-based tests in tuberculosis diagnostics. Finally, there are also reviewed the diagnostic tests and vaccines based on using such proteins currently being under development.

About the authors

Dmitry A. Kudlai

National Research Center — Institute of Immunology, Federal Medical-Biological Agency of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: D624254@gmail.com
ORCID iD: 0000-0003-1878-4467
SPIN-code: 4129-7880
Scopus Author ID: 921055

PhD, MD (Medicine), Professor of Pharmacology Department, Institute of Pharmacy; Leading Researcher, Laboratory of Personalized Medicine and Molecular Immunology

Russian Federation, Moscow; Moscow

N. P. Doktorova

National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation

Email: D624254@gmail.com

PhD, MD (Medicine), Researcher

Russian Federation, Moscow

References

  1. Аксенова В.А., Барышникова Л.А. Эффективность аллергена туберкулезного рекомбинантного при раннем выявлении туберкулезной инфекции у детей и подростков в условиях общей лечебной сети // Вопросы современной педиатрии. 2015. Т. 14, № 3. C. 358–362. [Aksenova V.A., Baryshnikova L.A. Efficacy of the recombinant tuberculosis allergen for early identification of latent tuberculosis in children and adolescents in general healthcare settings. Voprosy sovremennoi pediatrii = Current Pediatrics, 2015, vol. 14, no. 3, pp. 358–362. (In Russ.)] doi: 10.15690/vsp.v14i3.1371
  2. Аксенова В.А., Леви Д.Т., Александрова Н.В., Кудлай Д.А., Барышникова Л.А., Клевно Н.И. Туберкулез у детей: современные методы профилактики и ранней диагностики // Доктор.Ру. 2017. Т. 15, № 144. С. 9–15. [Aksenova V.A., Levi D.T., Aleksandrova N.V., Kudlay D.A., Baryshnikova L A., Klevno N.I. Pediatric TB: modern methods for prevention and early diagnostics. Doktor.Ru = Doctor.Ru, 2017, vol. 15, no. 144, рр. 9–15. (In Russ.)]
  3. Всемирная организация здравоохранения. Обновленное сводное руководство по программному ведению случаев латентной туберкулезной инфекции. Женева: Всемирная организация здравоохранения, 2018. 72 c. [Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. WHO, 2018. 72 p. (In Russ.)]
  4. Кожная проба с препаратом «Диаскинтест» — новые возможности идентификации туберкулезной инфекции. Под ред. М.А. Пальцева. 2-е изд., испр. и доп. М.: Шико, 2011. 256 с. [Skin test with the “Diaskintest” — new opportunities for the identification of tuberculosis infection. 2nd ed. Ed. by M.A. Pal’tsev. Moscow: Shiko Publ., 2011. 256 p. (In Russ.)]
  5. Козлова А.В., Лазарева Л.В., Вальц И.А. Анализ эффективности Диаскинтеста как метода верификации туберкулеза у детей // Universum медицина и фармакология. 2019. Т. 59, № 4. [Kozlova A.V., Lazareva L.V., Valts I.A. Analysis of efficiency of diaskintest as a method of verification of tuberculosis in children. Universum medicina i farmakologiya = Universum Medicine and Pharmacology, 2019, vol. 59, no. 4. (In Russ.)]
  6. Кудлай Д.А., Старшинова А.А., Довгалюк И.Ф. Аллерген туберкулезный рекомбинантный: 10-летний опыт применения теста у детей и подростков в Российской Федерации (данные метаанализа) // Педиатрия. Журнал имени Г.Н. Сперанского. 2020. Т. 99, № 3. С. 121–129. [Kudlay D.A., Starshinova A.A., Dovgalyuk I.F. Recombinant tuberculosis allergen: 10 years of experience with the test in children and adolescents in the Russian Federation (meta-analysis data). Pediatriya. Zhurnal imeni G.N. Speranskogo = Pediatria. Journal named after G.N. Speransky, 2020, vol. 99, no. 3, рр. 121–129. (In Russ.)] doi: 10.24110/0031-403X-2020-99-3-121-129
  7. Лозовская М.Э., Белушков В.В., Гурина О.П., Васильева Е.Б. Сравнительная оценка инновационных тестов в диагностике латентной и активной туберкулезной инфекции у детей // Педиатр. 2014. Т. 5, № 3. [Lozovskaya M.E., Belushkov V.V., Gurina O.P., Vasilyeva E.B. Comparative evaluation of innovative diagnostic tests for latent and active TВ infection in children. Pediatr = Pediatr, 2014, vol. 5, no. 3. (In Russ.)] doi: 10.17816/PED5346-50
  8. Лозовская М.Э., Белушков В.В., Гурина О.П., Дементьева Е.А., Шибакова Н.Д., Васильева Е.Б., Клочкова Л.В. Сопоставление лабораторных тестов Quantiferon, Тубинферон и Диаскинтеста у детей с туберкулезной инфекцией // Клиническая лабораторная диагностика. 2016. Т. 61, № 12. С. 838–842. [Losovskaya M.E., Belushkov V.V., Gurina O.P., Dementyeva E.A., Shibakova N.D., Vasilyeva E.B., Klochkova L.V. The comparison of laboratory tests Quantiferon, Tubinferon and Diaskintest in children with tuberculosis infection. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2016, vol. 61, no. 12, рр. 838–842. (In Russ.)] doi: 10.18821/0869-2084-2016-61-12-838-842
  9. Лозовская М.Э., Гурина О.П., Дементьева Е.А., Васильева Е.Б., Клочкова Л.В., Шибакова Н.Д., Белушков В.В. Особенности реагирования тестов in vitro и кожных проб с туберкулезными аллергенами в зависимости от варианта туберкулезной инфекции у детей // Медицина теория и практика. 2018. Т. 3, № 3. C. 13–18. [Lozovskaya M.E., Gurina O.P., Dementyeva E.A., Vasilyeva E.B., Klochkova L.V., Shibakova N.D., Belushkov V.V. Features of reaction in vitro tests and skin tests with tubercular allergens depending on variants of the tuberculosis infection in children. Medicina: teoriya i praktika = Medicine: Theory and Practice, 2018, vol. 3, no. 3, рр. 13–18. (In Russ.)]
  10. Мордовская Л.И., Гурьева О.И., Ильина, Е.Н., Тимофеева М.Н. Использование тест-системы «Тубинферон» и пробы с Диаскинтестом для диагностики туберкулеза органов дыхания у детей и подростков // Туберкулез и болезни легких. 2014. № 8. C. 70–71. [Mordovskaya L.I., Gurieva O.I., Ilyina, E.N., Timofeeva M.N. Use of the «Tubinferon» test system and samples with Diaskintest for the diagnosis of respiratory tuberculosis in children and adolescents. Tuberkulez i bolezni legkih = Tuberculosis and Lung Diseases, 2014, no. 8, pp. 70–71. (In Russ.)]
  11. Общероссийская общественная организация «Российское общество фтизиатров». Клинические рекомендации. Туберкулез у взрослых. 2020, 121 c. [All-Russian public organization “Russian Society of Phthisiologists”. Clinical guidelines. Tuberculosis in adults. 2020. 121 p. (In Russ.)]
  12. Российское Общество Фтизиатров. Клинические рекомендации. Туберкулез у детей. 2020. 59 c. [Russian Society of Phthisiatricians. Clinical guidelines. Tuberculosis in children. 2020. 59 p. (In Russ.)]
  13. Слогоцкая Л.В., Богородская Е.М., Леви Д.Т., Сельцовский П.П. 10 лет кожной пробе с аллергеном туберкулезным рекомбинантным (Диаскинтест) и 110 лет туберкулиновой пробе Манту — сравнение эффективности // Биопрепараты. Профилактика, диагностика, лечение. 2017. Т. 17, № 2. С. 67–77. [Slogotskaya L.V., Bogorodskaya E.M., Levi D.T., Seltsovsky P.P. Comparison of efficacy of Diaskintest®, a skin test with a recombinant tuberculosis allergen, used for 10 years and Mantoux tuberculin sensitivity test used for 110 years. Biopreparaty. Profilaktika, diagnostika, lechenie = Biopreparations. Prevention, Diagnosis, Treatment, 2017, vol. 17, no. 2, рр. 67–77. (In Russ.)]
  14. Слогоцкая Л.В., Сенчихина О.Ю., Никитина, Г.В., Богородская Е.М Эффективность кожного теста с аллергеном туберкулезным рекомбинантным при выявлении туберкулеза у детей и подростков Москвы в 2013 г. // Педиатрическая фармакология. 2015. Т. 12, № 1. С. 99–103. [Slogotskaya L.V., Senchikhina O.Yu., Nikitina G.V., Bogorodskaya E.M. Effectiveness of tuberculous recombinant allergen skin tests for detecting tuberculosis in children and adolescents of Moscow in 2013. Pediatricheskaya farmakologiya = Pediatric Pharmacology, 2015, vol. 12, no. 1, рр. 99–103. (In Russ.)] doi: 10.15690/pf.v12i1.1255
  15. Сотнева И.Б. Опыт применения аллергена туберкулезного рекомбинантного для массового обследования на туберкулез детей и подростков в Нижегородской области // Вопросы практической педиатрии. 2017. Т. 12, № 4. C. 43–48. [Sotneva I.B. An experience of using recombinant tuberculosis allergen for mass screening for tuberculosis among children and adolescents in the Nizhny Novgorod region. Voprosy prakticheskoj pediatrii = Clinical Practice in Pediatrics, 2017, vol. 12, no. 4, pp. 43–48. (In Russ.)] doi: 10.20953/1817-7646-2017-4-43-48
  16. Федеральная служба по надзору в сфере здравоохранения (Росздравнадзор). Тубинферон. ФСР 2011/11269, 2021. [Federal Service for Surveillance in Healthcare (Roszdravnadzor). Tubinferon. FSR 2011/11269, 2021. (In Russ.)] URL: https://roszdravnadzor.gov.ru/services
  17. Федеральное казначейство. Единая информационная система в сфере закупок, 2021. [Federal Treasury. Unified information system in the field of procurement, 2021. (In Russ.)] URL: https://zakupki.gov.ru/epz/main/public/home.html
  18. Шаповал И.Н. Здравоохранение в России. 2019: cтат. сб. М.: Росстат, 2019. 170 с. [Shapoval I.N. Healthcare in Russia. 2019: statistical collection. Moscow: Rosstat, 2019. 170 p. (In Russ.)]
  19. Adams L.V., Starke J.R. Latent tuberculosis infection in children. UpToDate, 2018. 12 p.
  20. Andersen P., Munk M.E., Pollock J.M., Doherty T.M. Specific immune-based diagnosis of tuberculosis. Lancet, 2000, vol. 356, no. 9235, pp. 1099–1104. doi: 10.1016/S0140-6736(00)02742-2
  21. Campbell J.R., Winters N., Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. Br. Med. J., 2020, vol. 368: m549. doi: 10.1136/bmj.m549
  22. Croke L.M. Tuberculosis: guidelines for diagnosis from the ATS, IDSA, and CDC. Am. Fam. Physician., 2018, vol. 97, no. 1, pp. 56–58.
  23. Da Costa C., Walker B., Bonavia A. Tuberculosis vaccines — state of the art, and novel approaches to vaccine development. Int. J. Infect. Dis., 2015, vol. 32, pp. 5–12. doi: 10.1016/j.ijid.2014.11.026
  24. Doan T.N., Eisen D.P., Rose M.T., Slack A., Stearnes G. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: a latent-class analysis. PLoS One, 2017, vol. 12, no. 11: e0188631. doi: 10.1371/journal.pone.0188631
  25. European Centre for Disease Prevention and Control. Review of reviews and guidelines on target groups, diagnosis, treatment and programmatic issues for implementation of latent tuberculosis management. Stockholm: ECDC, 2018. 127 p.
  26. Gong W., Liang Y., Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum. Vaccin. Immunother., 2018, vol. 14, no. 7, pp. 1697–1716. doi: 10.1080/21645515.2018.1458806
  27. Jurčev-Savičević A., Katalinić-Janković V., Miše K., Gudelj I. The role of interferon-gamma release assay in tuberculosis control. Arh. Hig. Rada Toksikol, 2012, vol. 63, no. 1, pp. 49–58. doi: 10.2478/10004-1254-63-2012-2134
  28. Lalvani A., Whitworth H.S. Progress in interferon-gamma release assay development and applications: an unfolding story of translational research. Ann. Transl. Med., 2019, vol. 7 (suppl. 3). doi: 10.21037/atm.2019.05.76
  29. Lewinsohn D.M., Leonard M.K., LoBue P.A., Cohn D.L., Daley C.L., Desmond E., Keane J., Lewinsohn D.A., Loeffler A.M., Mazurek G.H., O’Brien R.J., Pai M., Richeldi L., Salfinger M., Shinnick T.M., Sterling T.R., Warshauer D.M., Woods G.L. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin. Infect. Dis., 2017, vol. 64, no. 2, pp. e1–e33. doi: 10.1093/cid/ciw778
  30. Li F., Xu M., Qin C., Xia L., Xiong Y., Xi X., Fan X., Gu J., Pu J., Wu Q., Lu S., Wang G. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin. Microbiol., 2016, vol. 22, no. 10, pp. 889.e9–889.e16. doi: 10.1016/j.cmi.2016.07.015
  31. Menzies D. Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults. UpToDate, 2018. 15 p.
  32. Menzies D. Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults. UpToDate, 2018, 12 p.
  33. Menzies D., Schwartzman K., Pai M. Immune-based tests for tuberculosis. Tuberculosis, 2009, pp. 179–196.
  34. Nikitina I.Y., Karpina N.L., Kasimceva O.V., Gergert V.Y., Ergeshov A., Lyadova I.V. Comparative performance of QuantiFERON-TB Gold versus skin test with tuberculosis recombinant allergen (Diaskintest) among patients with suspected pulmonary tuberculosis in Russia. Int. J. Infect. Dis., 2019, vol. 86, pp. 18–24. doi: 10.1016/j.ijid.2019.06.014
  35. Pai M., Kalantri S., Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev. Mol. Diagn, 2006, vol. 6, no. 3, pp. 413–422. doi: 10.1586/14737159.6.3.413
  36. Refai A., Gritli S., Barbouche M.R., Essafi M. Mycobacterium tuberculosis virulent factor ESAT-6 drives macrophage differentiation toward the pro-inflammatory M1 phenotype and subsequently switches it to the anti-inflammatory M2 phenotype. Front. Cell. Infect. Microbiol., 2018. vol. 8: 327. doi: 10.3389/fcimb.2018.00327
  37. Ru H., Liu X., Lin C., Yang J., Chen F., Sun R., Zhang L., Liu J. The impact of genome region of difference 4 (RD4) on mycobacterial virulence and BCG efficacy. Front. Cell. Infect. Microbiol., 2017, vol. 7: 239. doi: 10.3389/fcimb.2017.00239
  38. Ruhwald M., Aggerbeck H., Gallardo R.V., Hoff S.T., Villate J.I., Borregaard B., Martinez J.A., Kromann I., Penas A., Anibarro L.L., de Souza-Galvão M.L., Andersen P., Caylá J.A. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir., 2017, vol. 5, no. 4, pp. 259–268. doi: 10.1016/S2213-2600(16)30436-2
  39. Slogotskaya L., Bogorodskaya E., Sentchichina O., Ivanova D., Nikitina G., Litvinov V., Seltsovsky P., Kudlay D., Nikolenko N., Borisov S. Effectiveness of tuberculosis detection using a skin test with allergen recombinant (CFP-10-ESAT-6) in children. Eur. Respiratory Soc., 2015, vol. 46: PA4524. doi: 10.1183/13993003.congress-2015.PA4524
  40. Starshinova A., Dovgalyk I., Malkova A., Zinchenko Y., Pavlova1 M., Belyaeva E., Basantsova N., Nazarenko M., Kudlay D., Yablonskiy P. Recombinant tuberculosis allergen (Diaskintest®) in tuberculosis diagnostic in Russia (meta-analysis). Int. J. Mycobacteriology, 2020, vol. 9, no. 4: 335. doi: 10.4103/ijmy.ijmy_131_20
  41. Starshinova A., Zhuravlev V., Dovgaluk I., Panteleev A., Manina V., Zinchenko U., Istomina E., Pavlova M., Yablonskiy P. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. Int. J. Mycobacteriol., 2018, vol. 7, no. 1, pp. 32–39. doi: 10.4103/ijmy.ijmy_17_18
  42. Van Pinxteren L.A., Ravn P., Agger E.M., Pollock J., Andersen P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab. Immunol., 2000, vol. 7, no. 2, pp. 155–160. doi: 10.1128/CDLI.7.2.155-160.2000
  43. Welin A., Björnsdottir H., Winther M., Christenson K., Oprea T., Karlsson A., Forsman H., Dahlgren C., Bylund J. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect. Immun. Am. Soc. Microbiol, 2015, vol. 83, no. 1, pp. 205–213. doi: 10.1128/IAI.02493-14
  44. Zhang H., Wang L., Li F., Lu S., Xia J. Induration or erythema diameter not less than 5 mm as results of recombinant fusion protein ESAT6-CFP10 skin test for detecting M. tuberculosis infection. BMC Infect. Dis., 2020, vol. 20: 685. doi: 10.1186/s12879-020-05413-9
  45. Zhou G., Luo Q., Luo S., Teng Z., Ji Z., Yang J., Bao F. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect. Dis., 2020, vol. 20, no. 12, pp. 1457–1469. doi: 10.1016/S1473-3099(20)30276-0

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Kudlai D.A., Doktorova N.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies